Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2003 Apr;12(2):101–105. doi: 10.1080/0962935031000097718

No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis.

Yves Denizot 1, Eric Liozon 1, Laurence Guglielmi 1, Kim Ly 1, Pascale Soria 1, Véronique Loustaud 1, Elisabeth Vidal 1, Marie Odile Jauberteau 1
PMCID: PMC1781601  PMID: 12775360

Abstract

BACKGROUND: Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases. AIMS: In this study, we ensured the role of PAF in SLE patients without renal complications. METHODS: Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A(2), and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls. RESULTS: Blood PAF levels were not different (p=0.45) between SLE patients (6.7+/-2.8 pg/ml) and healthy subjects (9.6+/-3.1 pg/ml). Plasma acetylhydrolase activity (the PAF-degrading enzyme) was significantly (p=0.03) elevated in SLE patients (57.8+/-6.4 nmol/min/ml) as compared with controls (37.9+/-2.6 nmol/min/ml). Plasma soluble phospholipase A(2) (the key enzyme for PAF formation) was not different (p=0.6) between SLE patients (59.1+/-5.1 U/ml) and controls (54.7+/-2.4 U/ml). Antibodies against PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients. CONCLUSION: This clinical study highlights no evidence for a putative important role of PAF in SLE patients without active nephritis.

Full Text

The Full Text of this article is available as a PDF (94.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammit A. J., O'Neill C. Comparison of a radioimmunoassay and bioassay for embryo-derived platelet-activating factor. Hum Reprod. 1991 Jul;6(6):872–878. doi: 10.1093/oxfordjournals.humrep.a137443. [DOI] [PubMed] [Google Scholar]
  2. Baldi E., Emancipator S. N., Hassan M. O., Dunn M. J. Platelet activating factor receptor blockade ameliorates murine systemic lupus erythematosus. Kidney Int. 1990 Dec;38(6):1030–1038. doi: 10.1038/ki.1990.309. [DOI] [PubMed] [Google Scholar]
  3. Baldo B. A., Smal M. A., McCaskill A. C. A specific, sensitive and high-capacity immunoassay for PAF. Lipids. 1991 Dec;26(12):1136–1139. doi: 10.1007/BF02536517. [DOI] [PubMed] [Google Scholar]
  4. Barquinero J., Ordi-Ros J., Selva A., Perez-Peman P., Vilardell M., Khamashta M. Antibodies against platelet-activating factor in patients with antiphospholipid antibodies. Lupus. 1994 Feb;3(1):55–58. doi: 10.1177/096120339400300111. [DOI] [PubMed] [Google Scholar]
  5. Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–640. doi: 10.1002/art.1780350606. [DOI] [PubMed] [Google Scholar]
  6. Bussolati B., Rollino C., Mariano F., Quarello F., Camussi G. IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE). Clin Exp Immunol. 2000 Dec;122(3):471–476. doi: 10.1046/j.1365-2249.2000.01392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Denizot Y., Aupetit C., Bridoux F., Alphonse J. C., Cogné M., Aldigier J. C. Deregulated platelet-activating factor levels and acetylhydrolase activity in patients with idiopathic IgA nephropathy. Nephrol Dial Transplant. 2000 Sep;15(9):1344–1347. doi: 10.1093/ndt/15.9.1344. [DOI] [PubMed] [Google Scholar]
  8. Denizot Y., Desplat V., Drouet M., Bertin F., Melloni B. Is there a role of platelet-activating factor in human lung cancer? Lung Cancer. 2001 Aug-Sep;33(2-3):195–202. doi: 10.1016/s0169-5002(01)00197-0. [DOI] [PubMed] [Google Scholar]
  9. Desplat V., Besse A., Faucher J. L., Praloran V., Denizot Y. Expression of platelet-activating factor receptor transcript-1 but not transcript-2 by human bone marrow cells. Stem Cells. 1999;17(2):121–124. doi: 10.1002/stem.170121. [DOI] [PubMed] [Google Scholar]
  10. Iatrou C., Moustakas G., Antonopoulou S., Demopoulos C. A., Ziroyiannis P. Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron. 1996;72(4):611–616. doi: 10.1159/000188948. [DOI] [PubMed] [Google Scholar]
  11. Imaizumi T. A., Stafforini D. M., Yamada Y., McIntyre T. M., Prescott S. M., Zimmerman G. A. Platelet-activating factor: a mediator for clinicians. J Intern Med. 1995 Jul;238(1):5–20. doi: 10.1111/j.1365-2796.1995.tb00894.x. [DOI] [PubMed] [Google Scholar]
  12. Izumi T., Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta. 1995 Dec 7;1259(3):317–333. doi: 10.1016/0005-2760(95)00171-9. [DOI] [PubMed] [Google Scholar]
  13. Leong K. H., Koh E. T., Feng P. H., Boey M. L. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol. 1994 Jul;21(7):1264–1267. [PubMed] [Google Scholar]
  14. López-Novoa J. M. Potential role of platelet activating factor in acute renal failure. Kidney Int. 1999 May;55(5):1672–1682. doi: 10.1046/j.1523-1755.1999.00450.x. [DOI] [PubMed] [Google Scholar]
  15. Matsuzaki M., Ishiguro Y., Tetsumoto T., Tsukada Y., Kayahara H., Tadasa K. PAF acetylhydrolase activities in human systemic lupus erythematosus and lupus-prone mice. Clin Chim Acta. 1992 Sep 15;210(1-2):139–144. doi: 10.1016/0009-8981(92)90052-r. [DOI] [PubMed] [Google Scholar]
  16. Mazer B. D., Sawami H., Franklin R., Gelfand E. W. B-cell activation and regulation of immunoglobulin synthesis by platelet activating factor. Neth J Med. 1991 Oct;39(3-4):244–253. [PubMed] [Google Scholar]
  17. McManus L. M., Woodard D. S., Deavers S. I., Pinckard R. N. PAF molecular heterogeneity: pathobiological implications. Lab Invest. 1993 Dec;69(6):639–650. [PubMed] [Google Scholar]
  18. Morigi M., Macconi D., Riccardi E., Boccardo P., Zilio P., Bertani T., Remuzzi G. Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. J Pharmacol Exp Ther. 1991 Aug;258(2):601–606. [PubMed] [Google Scholar]
  19. Nguer C. M., Treton D., Rola-Pleszczynski M., Mishal Z., Thomas Y., Galanaud P., Richard Y. Regulation of platelet-activating factor receptor expression in human B cells and B cell lines. Lipids. 1996 Oct;31(10):1051–1058. doi: 10.1007/BF02522462. [DOI] [PubMed] [Google Scholar]
  20. Shirasaki H., Adcock I. M., Kwon O. J., Nishikawa M., Mak J. C., Barnes P. J. Agonist-induced up-regulation of platelet-activating factor receptor messenger RNA in human monocytes. Eur J Pharmacol. 1994 Jul 15;268(2):263–266. doi: 10.1016/0922-4106(94)90197-x. [DOI] [PubMed] [Google Scholar]
  21. Smith C. S., Shearer W. T. Activation of NF-kappa B and immunoglobulin expression in response to platelet-activating factor in a human B cell line. Cell Immunol. 1994 May;155(2):292–303. doi: 10.1006/cimm.1994.1123. [DOI] [PubMed] [Google Scholar]
  22. Stafforini D. M., Prescott S. M., Zimmerman G. A., McIntyre T. M. Mammalian platelet-activating factor acetylhydrolases. Biochim Biophys Acta. 1996 Jun 11;1301(3):161–173. doi: 10.1016/0005-2760(96)00040-9. [DOI] [PubMed] [Google Scholar]
  23. Stafforini D. M., Satoh K., Atkinson D. L., Tjoelker L. W., Eberhardt C., Yoshida H., Imaizumi T., Takamatsu S., Zimmerman G. A., McIntyre T. M. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest. 1996 Jun 15;97(12):2784–2791. doi: 10.1172/JCI118733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  25. Tektonidou M. G., Petrovas C. A., Ioannidis J. P., Vlachoyiannopoulos P. G., Moutsopoulos H. M. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. Eur J Clin Invest. 2000 Jul;30(7):646–652. doi: 10.1046/j.1365-2362.2000.00673.x. [DOI] [PubMed] [Google Scholar]
  26. Tetta C., Bussolino F., Modena V., Montrucchio G., Segoloni G., Pescarmona G., Camussi G. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1990;91(3):244–256. doi: 10.1159/000235124. [DOI] [PubMed] [Google Scholar]
  27. Vilá L. M., Mayor A. M., Valentín A. H., García-Soberal M., Vilá S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000;9(2):110–115. doi: 10.1191/096120300678828073. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES